WuXi and the BIOSECURE Act: legal architecture, affiliate risk, and who wins

Research evidence excerpt

WuXi and the BIOSECURE Act: legal architecture, affiliate risk, and who wins

eously chairs both

WuXi AppTec and WuXi Biologics, chairs the latter's Nomination Committee, and controls the largest

single shareholder block (8.7%). WuXi Biologics' own financial statements describe both entities as

sharing a common founding group with "significant influence" over the holding structure. Whether this

constitutes "control" under the relevant statutory definitions is not for us to determine, but the US

government applies a functional test that extends well beyond simple equity ownership.

Customer de-risking is already underway, ahead of formal timelines. WuXi AppTec's injunction filing

cites seven specific customer actions within ten days of designation, and multiple law firms have issued

advisories directing clients to prepare. BIOSECURE's formal prohibitions may not bite until 2028, and

existing contracts benefit from a five-year grandfathering period, but the portfolio-level nature of the

restriction, where a single WuXi dependency anywhere in a company's programmes could jeopardise

enterprise-wide federal contracting eligibility, creates pressure to eliminate relationships entirely rather

than manage them case by case.

TIDES is the most concentrated displacement opportunity. WuXi AppTec accounts for c.50% (c.$1.6bn)

of combined revenue among the four largest outsourced TIDES providers, in a market that already

appears capacity-constrained. Bachem and Polypeptide are the primary listed Western alternatives,

with Bachem's Building K (peak capacity c.CHF800m) now ramping and Polypeptide midway through

its own roll-out. Any enforced market share shift would be incremental to the demand these capacity

additions were originally built to serve.